Previously, our Chief Operating Officer Sultan Beardsley outlined an investment thesis for RegenXBio. This detailed report can be read here: Could This Biotech Stock Get Bought For $5.5 Billion? … [Read more...] about An Update on RegenXBio
After a recent selloff in mid June 2019, Stock price went from from $6.70 down to $3.44. Calithera Bio-sciences (Nasdaq: CALA) looks to have established a double bottom. New strong uptrend suggests it … [Read more...] about CALITHERA Initiates & Potential Buying Opportunity
EYPT | Range bound by follow_the_money on TradingView.com Long-Term pattern suggests that after previous dilution, Eyepoint Pharmaceuticals (Nasdaq: EYPT) stock price went range bound for quite … [Read more...] about Eyepoint’s Range Bound, Swing Opportunity?
ESG has been a hot topic amongst the investment community recently. As climate catastrophe looms closer and closer, millennials mature and demand more from corporations and other factors continue to … [Read more...] about Mutual Fund LDVAX Booked 37%+ Returns, Is It Still A Buy?
Now that we are in the heat of summer the books have closed for the first half of the year. Here in the exclusive piece for our subscribers in which our team will individually reflect on our first … [Read more...] about MS Conference Call Exclusive: Reflecting on the 1st Half of 2019
Recent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company … [Read more...] about Sangamo Therapeutics Inc.(Nasdaq: SGMO) – Doom Or Gloom Scenario